Labetalol, an antihypertensive agent, which is metabolized primarily by UGT1A1 glucuronidation, shows increased clearance in the second and third trimesters of pregnancy compared to the postpartum period.8 Lamotrigine, an antiepileptic agent metabolized by UGT1A3 and UGT1A4, has a 50% decreased elimination half-life with an increased clearance of over 200% during pregnancy, leading to a closely correlated higher incidence of epileptic seizures.9 Labetalol and lamotrigine clearance during pregnancy indicates that UGT1A1, UGT1A3, and UGT1A4 are induced and clearance is accelerated. The gene discussed is UGT1A1; the disease is Seizure.